The role of the immunoescape in colorectal cancer liver metastasis

The expression of programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) indicate the efficacy of anti-PD-1/PD-L1 therapy in colorectal cancer (CRC), but are less useful for monitoring the efficacy of therapy of CRC liver metastasis (CRLM). This study investigated the effects of immune mole...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Chie Takasu, Shoko Yamashita, Yuji Morine, Kozo Yoshikawa, Takuya Tokunaga, Masaaki Nishi, Hideya Kashihara, Toshiaki Yoshimoto, Mitsuo Shimada
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9591f4f9318f47abb5725c5860fd1b6e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9591f4f9318f47abb5725c5860fd1b6e
record_format	dspace
spelling	oai:doaj.org-article:9591f4f9318f47abb5725c5860fd1b6e2021-11-25T06:19:26ZThe role of the immunoescape in colorectal cancer liver metastasis1932-6203https://doaj.org/article/9591f4f9318f47abb5725c5860fd1b6e2021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604373/?tool=EBIhttps://doaj.org/toc/1932-6203The expression of programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) indicate the efficacy of anti-PD-1/PD-L1 therapy in colorectal cancer (CRC), but are less useful for monitoring the efficacy of therapy of CRC liver metastasis (CRLM). This study investigated the effects of immune molecules on the prognosis of CRLM. We enrolled 71 patients with CRLM who underwent curative resection for CRC. We used immunohistochemistry to analyze the expression of PD-1, PD-L1, indoleamine-pyrrole 2,3-dioxygenase (IDO), and CD163 (a marker of tumor-associated macrophages [TAMs]) in metastatic tumors. The immune molecules PD-1, PD-L1, IDO, and TAMs were expressed in 32.3%, 47.8%, 45.0%, and 47.9% of metastatic CRC samples, respectively. The 5-year overall survival rates associated with immune molecule-positive groups were significantly better than in the negative groups (PD-1: 87.7% vs 53.2%, p = 0.023; PD-L1: 82.4% vs 42.3%, p = 0.007; IDO: 80.7% vs 43.5%, p = 0.007; TAMs: 82.6% vs 48.0%, p = 0.005). Multivariate analysis revealed PD-1 expression (p = 0.032, hazard ratio: 0.19), IDO expression (p = 0.049, hazard ratio: 0.37), and tumor differentiation (p<0.001, hazard ratio: 0.02) as independent prognostic indicators. PD-1 and TAMs in metastases were associated with less aggressive features such as smaller tumors. Furthermore, TAMs positively and significantly correlated with PD-1 expression (p = 0.011), PD-L1 expression (p = 0.024), and tended to correlate with IDO expression (p = 0.078). PD-1, PD-L1, IDO, and TAMs in CRLM were associated with less aggressive features and better prognosis of patients with CRC, indicating adaptive antitumor immunity vs immune tolerance. These molecules may therefore serve as prognostic markers for CRLM.Chie TakasuShoko YamashitaYuji MorineKozo YoshikawaTakuya TokunagaMasaaki NishiHideya KashiharaToshiaki YoshimotoMitsuo ShimadaPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Chie Takasu Shoko Yamashita Yuji Morine Kozo Yoshikawa Takuya Tokunaga Masaaki Nishi Hideya Kashihara Toshiaki Yoshimoto Mitsuo Shimada The role of the immunoescape in colorectal cancer liver metastasis
description	The expression of programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) indicate the efficacy of anti-PD-1/PD-L1 therapy in colorectal cancer (CRC), but are less useful for monitoring the efficacy of therapy of CRC liver metastasis (CRLM). This study investigated the effects of immune molecules on the prognosis of CRLM. We enrolled 71 patients with CRLM who underwent curative resection for CRC. We used immunohistochemistry to analyze the expression of PD-1, PD-L1, indoleamine-pyrrole 2,3-dioxygenase (IDO), and CD163 (a marker of tumor-associated macrophages [TAMs]) in metastatic tumors. The immune molecules PD-1, PD-L1, IDO, and TAMs were expressed in 32.3%, 47.8%, 45.0%, and 47.9% of metastatic CRC samples, respectively. The 5-year overall survival rates associated with immune molecule-positive groups were significantly better than in the negative groups (PD-1: 87.7% vs 53.2%, p = 0.023; PD-L1: 82.4% vs 42.3%, p = 0.007; IDO: 80.7% vs 43.5%, p = 0.007; TAMs: 82.6% vs 48.0%, p = 0.005). Multivariate analysis revealed PD-1 expression (p = 0.032, hazard ratio: 0.19), IDO expression (p = 0.049, hazard ratio: 0.37), and tumor differentiation (p<0.001, hazard ratio: 0.02) as independent prognostic indicators. PD-1 and TAMs in metastases were associated with less aggressive features such as smaller tumors. Furthermore, TAMs positively and significantly correlated with PD-1 expression (p = 0.011), PD-L1 expression (p = 0.024), and tended to correlate with IDO expression (p = 0.078). PD-1, PD-L1, IDO, and TAMs in CRLM were associated with less aggressive features and better prognosis of patients with CRC, indicating adaptive antitumor immunity vs immune tolerance. These molecules may therefore serve as prognostic markers for CRLM.
format	article
author	Chie Takasu Shoko Yamashita Yuji Morine Kozo Yoshikawa Takuya Tokunaga Masaaki Nishi Hideya Kashihara Toshiaki Yoshimoto Mitsuo Shimada
author_facet	Chie Takasu Shoko Yamashita Yuji Morine Kozo Yoshikawa Takuya Tokunaga Masaaki Nishi Hideya Kashihara Toshiaki Yoshimoto Mitsuo Shimada
author_sort	Chie Takasu
title	The role of the immunoescape in colorectal cancer liver metastasis
title_short	The role of the immunoescape in colorectal cancer liver metastasis
title_full	The role of the immunoescape in colorectal cancer liver metastasis
title_fullStr	The role of the immunoescape in colorectal cancer liver metastasis
title_full_unstemmed	The role of the immunoescape in colorectal cancer liver metastasis
title_sort	role of the immunoescape in colorectal cancer liver metastasis
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/9591f4f9318f47abb5725c5860fd1b6e
work_keys_str_mv	AT chietakasu theroleoftheimmunoescapeincolorectalcancerlivermetastasis AT shokoyamashita theroleoftheimmunoescapeincolorectalcancerlivermetastasis AT yujimorine theroleoftheimmunoescapeincolorectalcancerlivermetastasis AT kozoyoshikawa theroleoftheimmunoescapeincolorectalcancerlivermetastasis AT takuyatokunaga theroleoftheimmunoescapeincolorectalcancerlivermetastasis AT masaakinishi theroleoftheimmunoescapeincolorectalcancerlivermetastasis AT hideyakashihara theroleoftheimmunoescapeincolorectalcancerlivermetastasis AT toshiakiyoshimoto theroleoftheimmunoescapeincolorectalcancerlivermetastasis AT mitsuoshimada theroleoftheimmunoescapeincolorectalcancerlivermetastasis AT chietakasu roleoftheimmunoescapeincolorectalcancerlivermetastasis AT shokoyamashita roleoftheimmunoescapeincolorectalcancerlivermetastasis AT yujimorine roleoftheimmunoescapeincolorectalcancerlivermetastasis AT kozoyoshikawa roleoftheimmunoescapeincolorectalcancerlivermetastasis AT takuyatokunaga roleoftheimmunoescapeincolorectalcancerlivermetastasis AT masaakinishi roleoftheimmunoescapeincolorectalcancerlivermetastasis AT hideyakashihara roleoftheimmunoescapeincolorectalcancerlivermetastasis AT toshiakiyoshimoto roleoftheimmunoescapeincolorectalcancerlivermetastasis AT mitsuoshimada roleoftheimmunoescapeincolorectalcancerlivermetastasis
_version_	1718413878709190656

The role of the immunoescape in colorectal cancer liver metastasis

Ejemplares similares